INTRODUCTION
Chemically, Hydrochlorothiazide 2 (HCT) is 6-chloro-1, 1-dio xo-3, 4-dihydro-2H-1, 2, 4-ben zothiadiazine-7 sulfonamide wh ich is a first line diuretic drug of the thiazide class (Figure 2 ). It acts by lowering blood pressure initially by increasing sodium and water excretion. Th is causes a decrease in extracellu lar volu me, resulting in a decrease in cardiac output and renal blood flow. W ith long-term treat ment, plasma volu me approaches a normal value, but peripheral resistance decreases. Literature survey reveals that s pectrophotometric 3 , LC 4 and LC-MS 5 methods were developed for the analysis of Candesartan cilexetil alone and three HPLC methods were proposed for the estimat ion of Hydrochlorothiazide [6] [7] [8] alone in bio logical fluids.
Very few analytical methods such as spectrophotometric 9 , HPLC [10] [11] [12] and HPTLC 13 method have been developed till
ABS TRACT
A simple and sensitive RP-HPLC method was developed and validated for the determination of Candesartan cilexetil and Hydrochlorthiazide in pharmaceutical dosage forms. The separation of components was achieved on a SHIM ADZU Hypersil ODS-C 18 column (250 × 4.6 mm, 5 µm) with UV detection at 270 nm. Isocratic elution with a mobile phase consisting of 10 mM (pH 3.37) Tetra butyl ammonium hydrogen sulphate: methanol (15:85, V/V), at a flow rate 1.0 mL min -1 was employed. Linearity was observed in the concentration range 0.625-62.5 µg/mL for Hydrochlorthiazide and 0.8-80 µg/mL for Candesartan cilexetil respectively. The linear regression equation was found to be Y=64002X-1412.6 for Hydrochlorthiazide and Y=24649X-6701.8 for Candesartan cilexetil respectively with correlation coefficients greater than 0.999. The LOD was found to be 0.1385 and 0.1892 µg/mL for Hydrochlorthiazide and Candesartan cilexetil respectively where as the LOQ was found to be 0.4394 and 0.6187 µg/mL for Hydrochlorthiazide and Candesartan cilexetil respectively. The mean analytical recovery in determination of Candesartan cilexetil and Hydrochlorthiazide tablets was 99.31-100.08% Hydrochlorthiazide and 99.58-100.39% for Candesartan cilexetil respectively. Thus, the proposed method is applicable for routine determination of Candesartan cilexetil and Hydrochlorthiazide in pharmaceutical formulations. IS SN: 2250-1177 now for the simu ltaneous determination of Candesartan cilexetil and Hydrochlorothiazide in pharmaceutical formulat ions and biological fluids. The objective of this investigation is to develop an efficient, simple, rapid, validated and reliable method for the routine quality control analysis for the simu ltaneous determination of Candesartan cilexetil and Hydrochlorthiazide in pharmaceutical preparations.
MATERIALS AND METHODS

Instrumentation
A Shimadzu HPLC instrument (LC-10AT Vp) equipped with UV-Vis ible detector, manual in jector with 20 µl sample loop and A Hibar 250 x 4.6 mm LiChrospher 100 C 18 column (250 mm x 4.6 mm i.d., 5 µm part icle size) was used. The output signal was monitored and integrated using Shimadzu Class-Vp version 6.12 SP1 software was used for separation.
Reagents and Materials
Ranbaxy Laboratories Limited, India, kindly gifted Candesartan cilexetil and Hydrochlorthiazide pure powder with 99.98% and 99.98% purity respectively. HPLC grade methanol was purchased from Merck, India. The water for HPLC was obtained from TKA Gen Pure (Pacific) system (Germany). Tetra butyl ammon iu m hydrogen sulphate was purchased from S.D. Fine Chemicals, Ahmedabad, India and was of analytical grade. CANDELONG-H® (Candesartan cilexetil 8 mg and Hydrochlorthiazide 12.5 mg) and CANDESA R-H® (Candesartan cilexet il 16 mg and Hydrochlorthiazide 12.5 mg) brands are available as tablet.
Chromatographic Condi tions
A Shimad zu C 18 column (250 mm x 4.6 mm i.d., 5 µm) was used at ambient temperature. The mobile p hase comprised of 0.01 M Tetra butyl ammon iu m hydrogen sulphate (pH 3.37) and methanol (15:85 v/v) was prepared, filtered through nylon 0.45 mm memb rane filter and degassed before use. The mobile phase was pumped at a flow rate of 1 mL/ min and the elution was mon itored at 270 n m. The injection volu me was 20 µL.
Preparation of Hydrochlorthi azi de and Candesartan cilexetil Standard Soluti ons
Accurately weighed Hydrochlorthiazide (6.25 mg) and Candesartan cilexetil (8.0 mg ) were transferred to a 100 mL volu metric flask, dissolved in and diluted to the mark with mobile phase to obtain a standard solution having a concentration of Hydrochlorthiazide (62.5 µg/ mL) and Candesartan cilexetil (80 µg/mL). Th is solution was further diluted to obtain working standard solutions with Hydrochlorthiazide (0.625 -62.5 µg/mL) and Candesartan cilexetil (0.8-80 µg/ mL) for the HPLC method.
Preparation of Sample Solutions
Powder of each of 20 tablets (2 brands, CANDESA R-H® and CANDELONG-H®) were weighed and analyzed as follows. A mass of tablet powder equivalent to the powder of one tablet was weighed from each brand and transferred in to a 100 mL volu metric flask separately and methanol (80 mL) was added. It was sonicated for 15 minutes and final volu me was made up to the mark with methanol to get a solution with Hydrochlorthiazide (62.5 µg/ mL) and Candesartan cilexet il (80 µg/ mL) for brand I (CA NDESAR-H®) and Hydrochlorthiazide (62.5 µg/mL) and Candesartan cilexetil (40 µg/mL) for brand II (CA NDELONG-H®). Each mixtu re was then filtered separately through a nylon membrane filter.
Method Vali dation
Specificity (Selecti vity)
The selectivity of the RP HPLC method was checked by comparison of chromatograms obtained fro m samples and the corresponding placebo. Additives in tablets are sparingly soluble in methanol or the mobile phase, whereas the active constituents are freely soluble.
Linearity
Calibrat ion curves were constructed by plotting peak areas versus concentrations of Hydrochlorthiazide and Candesartan cilexetil and the regression equations were calculated. A calibration curve was plotted over a concentration range 0.625-625 µg/ mL for Hydrochlorthiazide and 0.8-80 µg/ mL for Candesartan cilexetil respectively. Accurately measured standard working solutions of Hydrochlorthiazide (0.625-62.5 µg/mL) and Candesartan cilexetil (0.8-80 µg/mL) were prepared in a series of 10 mL volu metric flasks and diluted to the mark with mobile phase. 20 µL of these solutions were injected under operating chro matographic conditions at UV detection 270 n m and the peak area was recorded.
Precision
The precision was checked by repeatedly (n = 3) inject ing standard solutions of three different concentrations of Hydrochlorthiazide (12.5, 25 and 50 µg/mL) and Candesartan cilexet il (16, 32 and 64 µg/mL) respectively.
Intermedi ate Precision (Reproduci bility)
The intra-day and inter-day precisions of the proposed methods were determined by estimating the corresponding responses 3 times on the same day and on 3 different days, over a period of 1 week, for 3 different concentrations of 12.5, 25 and 50 µg/ mL Hydrochlorthiazide and 16, 32 and 64 µg/mL for Candesartan cilexetil. The results are reported in terms of relative standard deviation.
The stability of standard solutions can also affect the robustness of analytical methods. The stability of the standard solutions of the drug substances us ed in these methods was tested over a long period of t ime. One port ion of a standard solution was kept at room temperature and another portion was stored under refrigeration at approximately 48ºC, and the content of these solutions was regularly co mpared with that of a freshly prepared solution.
Accuracy (% Recovery)
The accuracy of the methods was determined by calculating recoveries of 
Li mit of Detection and Li mit of Quantification
Experimentally the detection limit is defined as the concentration of the analyte producing a signal which is at least three times the base line noise measured from peak to peak and the quantitation limit is defined as the concentration of the analyte producing the signal which is at least ten times the base line noise. The limit of detection and the limit of quantification of the drug were calcu lated using the following equations as per ICH 14 guidelines. LOD = 3.3 × σ / S LOQ = 10 × σ / S Where σ = the standard deviation of the response, S = the standard deviation of y-intercept of regression lines.
Analysis of CST and HCT in Combi ned Tablet Dosage Form
Tablets containing Candesartan cilexet il and Hydrochlorthiazide of the two b rands CANDESA R-H® and CANDELONG-H®) were purchased from the local market and the drugs were extracted using the mobile phase. The response of tablet dosage forms was measured at 270 n m for quantificat ion of Candesartan cilexet il and Hydrochlorthiazide respectively as described above. The amount of Candesartan cilexet il and Hydrochlorthiazide present in sample solutions were determined by fitting the responses into the regression equation for Candesartan cilexetil and Hydrochlorthiazide. Retenti on Ti me 
RES ULTS AND DISCUSS ION
To optimize the HPLC parameters, several mob ile phase compositions were tried. A satisfactory separation and peak symmetry for Candesartan cilexetil and Hydrochlorthiazide were obtained with a mob ile phase mixtu re consisting of 0.01 M (pH 3.37) Tetra butyl ammon iu m hydrogen Sulphate and methanol (15:85 v/v) to get better reproducibility and repeatability. Quantificat ion was achieved with UV detection at 270 nm (Figure 3) based on peak area. The retention times were 8.100 and 2.750 mins for Candesartan cilexet il and Hydrochlorthiazide respectively. A good resolution of the peaks with clear base line separation was found (Figure 4 ). The present proposed method has been compared with the previously published liquid chromatographic methods in Table 1 Candesartan cilexet il and Hydrochlorthiazide respectively. The low % RSD values of intra-day and inter-day variations reveal that the proposed methods precise (Table  3 and 4). Table 3 : Intra-day and inter-day precision for Candesartan cilexetil (n = 3)
Conc. (µg/ mL)
Intra-day precision
Inter-day precision 
SD = Standard deviation. RSD = Relative standard deviation
Because the stability of standard solutions can also affect the robustness of analytical methods, the stability of the standard solutions of the drug substances used in these methods were tested over a long period of t ime. One portion of a standard solution was kept at roo m temperature and the other portion was stored under refrigeration at appro ximately 48C, and the content of these solutions was regularly co mpared with that of a freshly prepared solution. No changes in drug concentrations were observed for solutions stored under refrigeration. But, it is recommended that the standard and sample solutions must, therefore, be freshly prepared in amber colo red flasks to protect from light for both of the methods.
Accuracy
The recovery experiments were carried out by a standard addition method. The percent recoveries obtained were 99.31-100.08 and 99.58-100.39 for Candesartan cilexetil and Hydrochlorthiazide respectively ( Table 5 ). The low value of % RSD indicates that the method is accurate. 
Li mit of Detection and Li mit of Quantification
The LOD was found to be 0.1385 and 0.1892 µg/mL for Hydrochlorthiazide and Candesartan cilexet il respectively where as the LOQ was found to be 0.4394 and 0.6187 µg/mL for Hydrochlorthiazide and Candesartan cilexetil respectively.
System suitability
As system suitability test is an integral part of chromatographic methods development and it is used to verify that the system is adequate for the analysis to be performed, the parameter for Candesartan cilexet il and Hydrochlorthiazide was evaluated. The theoretical plates were found to be 4723 and 5435 (N >2000) for Candesartan cilexetil and Hydrochlorthiazide and the resolution was >1.5. The tailing factor was found to be 1.04 and 1.12) for Candesartan cilexet il and Hydrochlorthiazide respectively and the capacity factor (k') was found to be >2.0 fo r both.
Assay of the Tablet Dosage Forms
The proposed validated methods were successfully applied to determine Candesartan cilexet il and Hydrochlorthiazide in their comb ined tablet dosage form and a model chromatogram obtained from the marketed formulat ion was shown in Figure 5 . The results obtained for Candesartan cilexetil and Hydrochlorthiazide was comparable with the corresponding labeled amounts (Table 6 ). Table 6 : Analysis of co mmercial formulat ion (Tablets)
CONCLUS ION
The results of the analysis of pharmaceutical dosage forms by the proposed methods are highly reproducible, reliab le, and are in good agreement with the label claims of the drug. The additives usually present in the pharmaceutical formulat ions of the assayed samples did not interfere with Candesartan cilexet il and Hydrochlorthiazide. It may be said that the proposed methods are precise, sensitive, and accurate, so that these can be used as standard pharmacopoeial methods for the simultaneous determination of Candesartan cilexetil and Hydrochlorthiazide in tablets using the HPLC systems.
The advantages of the proposed method involve a simple procedure for sample preparat ion and relatively short time of analysis. Apart from th is, it can be used for assays of Candesartan cilexetil and Hydrochlorthiazide in biological flu ids or in pharmacokinetic investigations.
